Physician profile
Brian K Bizik
NPI 1932166956
$80,943.12
in general payments reported to CMS, 2019-2025
19 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $7,327 · 2023: $8,260 · 2024: $24K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $9,901 · Honoraria: $6,650 · Food and Beverage: $6,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,516.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,531.45 |
| Travel and Lodging | $9,901.27 |
| Honoraria | $6,650.00 |
| Food and Beverage | $6,341.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $16,239.14 | 2024-2025 | Vtama |
| Dermavant Sciences, INC. | $13,521.98 | 2024 | Tapinarof, Vtama |
| Grifols USA, LLC | $13,398.13 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $9,760.47 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $8,963.08 | 2021-2024 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $4,776.96 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Pfizer INC. | $4,200.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,376.79 | 2021-2022 | |
| Genzyme Corporation | $2,112.78 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,656.00 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,561.91 | 2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $1,375.00 | 2023 | |
| Blueprint Medicines Corporation | $375.01 | 2023-2024 | Ayvakit |
| Grifols Shared Services North America, INC. | $270.00 | 2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $132.76 | 2024 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $125.00 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $43.97 | 2024 | Nucala |
| Teva Pharmaceuticals USA, INC. | $36.83 | 2022 | |
| Amgen INC. | $17.31 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bizik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.